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Abstract  
Up to 80% of patients with diabetes mellitus develop lower urinary tract complications, most 
commonly diabetic bladder dysfunction (DBD). The aim of this study was to investigate the 
impact of diabetes on the function of the inner bladder lining (urothelium). Bladder compliance 
and intraluminal release of urothelial mediators (ATP and ACh) in response to distension was 
investigated in whole bladders isolated from 2 and 12-week streptozotocin (STZ)-diabetic rats. 
Intact and urothelium-denuded bladder strips were used to assess the influence of the 
urothelium on bladder contractility. Intraluminal ATP release was significantly enhanced at 2 
weeks of diabetes, although not at 12 weeks. In contrast, intraluminal ACh release was 
unaltered by diabetes. Bladder compliance was also significantly enhanced at both 2 and 12 
weeks, of diabetes, with greatly reduced intravesical pressures in response to distension.  Nerve-
evoked contractions of bladder strips were significantly greater at 2 weeks of diabetes. When 
the urothelium was absent nerve-evoked contractions were reduced, but contractions remained 
significantly elevated at lower frequencies of stimulation (<5Hz) in diabetics. Interestingly, 
although relaxations of bladder strips to isoprenaline were unaltered by diabetes, removal of 
the urothelium unmasked significantly enhanced relaxations in strips from 2-week and 12-week 
diabetic animals. In conclusion, diabetes alters urothelial function. Enhanced urothelial ATP 
release may be involved in the hypercontractility observed at early time points of diabetes. 
These alterations are time-dependent and may contribute to the mechanisms at play during the 
development of diabetic bladder dysfunction.                
 
 
Key words: ATP, urothelium, bladder dysfunction, diabetic complications, streptozotocin, 
diabetes mellitus  
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Introduction 
Lower urinary tract complications are amongst the most common and costly complications of 
diabetes mellitus, and have been estimated to affect up to 87% of patients with diabetes1, a rate 
greater than that of the widely known, and more widely researched complications, neuropathy 
and nephropathy2. In particular, approximately 50% of patients diagnosed with diabetes are 
affected by diabetic bladder dysfunction3, a condition characterized by a wide range of clinical 
symptoms, from problems with storage through to voiding symptoms4. Patients may have 
impaired voiding reflexes, that result in increased residual volumes at the end of urination, 
increased bladder capacity, decreased bladder sensation and decreased rates of contraction of 
the bladder wall5. Alternatively, diabetic bladder dysfunction can also present as overactive 
bladder, with distressing storage symptoms including urinary urgency, frequency, nocturia and 
incontinence3, 4. Thus, diabetic bladder dysfunction has a huge impact on patient quality of life 
and is a significant healthcare burden.  
 
The pathogenesis of diabetic bladder dysfunction is not well understood. Studies have 
characterised both functional and structural changes within the bladder, including changes in 
bladder function and contractility6-11, as well as alterations in bladder morphology, innervation 
and vasculature12, 13. These changes are temporal in nature6, 7, with the bladder undergoing a 
transition from a compensated state to a decompensated state with the duration and severity of 
diabetes6.  However, alterations within the inner lining of the bladder, the urothelium, have been 
less well researched, particularly with relation to function.  
 
The urothelium, whilst acting as a barrier to the urine, plays an essential role in signal 
transduction to the underlying nerves, smooth muscle and interstitial cells, influencing bladder 
function via the release of mediators including ATP and acetylcholine (ACh) during bladder 
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filling14. Diabetes has been shown to alter the bladder histologically, with progressive 
hypertrophy of the smooth muscle and urothelium with time10. Time-dependent breaches in the 
barrier structure of the urothelium, and upregulation of muscarinic and purinergic receptor 
expression, have also been reported15. This suggests that urothelial function may be altered in 
diabetes, although only a few studies have investigated this. These studies have demonstrated 
decreased release of prostaglandin E2 and F2α from isolated urothelial layers16, and increased 
ATP release along with depressed nitric oxide release in bladders from 4-week diabetic rats17. 
Urine PGE2 has also been shown to be decreased in 12-week diabetic rats18.  To date, there are 
no reports on the effects of diabetes on the release of the other key urothelial mediator, ACh. 
In addition, it is not clear whether alterations in ATP release vary with duration of diabetes. 
Thus, despite the growing evidence for the importance of the urothelium in bladder function, 
the impact of diabetes on urothelial function has not yet been fully elucidated. The aim of the 
study was to investigate urothelial mediator release from isolated whole bladders from 
streptozotocin-diabetic rats and the influence of the urothelium in modulating contractility of 
bladder strips.   
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Results  
Effect of Diabetes on Animal Parameters 
2-week diabetic animals lost body weight relative to age-matched controls (P<0.01), and 12 
week diabetic animals gained significantly less weight (P<0.001) over the 12-week period 
compared to age-matched controls (Table 1). Bladder weights were significantly greater than 
age-matched controls at both time points (Table 1).  Blood glucose levels greater than 30mM 
were displayed on the glucometer as ‘high’, and all diabetic animals had blood glucose levels 
greater than 30mM (Table 1).  
 
Effect of Diabetes on Bladder Compliance 
Isolated whole bladders were infused with saline to a volume of 1200µl, which would normally 
increase intraluminal pressure close to the threshold required for initiation of voiding.  Bladders 
from 2-week diabetic animals were significantly more compliant than control bladders, and 
intraluminal pressure did not rise above 10mmHg during the filling period. The intraluminal 
pressure recorded following distension was significantly reduced in bladders from 2-week 
diabetic animals (2.52±0.15mmHg, P<0.001) compared to controls (35.60±7.20mmHg) (Fig. 
1a), and in 12-week diabetic animals compared to controls (3.50±0.93mmHg vs 10.15±0.83, 
P<0.001) (Fig. 1b).  
 
Effect of Diabetes on Intraluminal Mediator Release  
Upon distension of whole bladders to a low volume (375µl), intraluminal ATP release was 
below the level of quantification.  ATP release following distension to a high volume (1200µl) 
was however significantly greater (P<0.05) in bladders from 2-week diabetic animals compared 
to controls (Fig. 2a).  At 12 weeks of diabetes intraluminal ATP release was similar to controls 
(Fig. 2a).   
6 
 
 
 
 
Intraluminal ACh was released following distension of bladders to both low and high volume. 
Diabetes of 2 and 12-weeks duration did not alter ACh release (Fig. 2b).  ACh release was 
consistently less in samples collected following high volume distensions compared to low 
volume distensions (Fig. 2b).   
 
Effects of Diabetes on Contractility of Isolated Bladder Strips   
Electrical field stimulation evoked efferent-nerve mediated contractions of bladder strips, 
which were completely abolished by tetrodotoxin (1µM) (data not shown). Nerve-evoked 
contractions were significantly greater in 2-week diabetic animals versus controls (Fig. 3a), 
however there was no significant difference between 12-week diabetic and age-matched 
controls (Fig. 3b).  Upon removal of the urothelium, nerve-evoked contractions remained 
significantly elevated in strips from 2-week diabetics only at the lower frequencies (<5Hz) (Fig. 
3c). This effect was also observed in strips from 12-week diabetic animals (Fig. 3d).  
 
Carbachol caused contractions of bladder strips, which were unaffected by diabetes (Fig. 4). 
Maximal contractions (2.21±0.23 and 2.31±0.41 mN/mg) and potency (pEC50, negative log of 
the EC50) of carbachol (5.84±0.09 and 5.74±0.08) were similar in strips from 2-week control 
and 2-week diabetics respectively. In strips from 12-week controls and diabetics, maximum 
responses and potency of carbachol were also similar (1.16±0.13 and 0.92±0.17 mN/mg, pEC50 
6.28±0.09 and 6.22±0.09 respectively). Removal of the urothelium did not affect carbachol-
induced contractions in any of the animal groups (Fig. 4). 
 
Addition of KCl produced a pre-contraction of bladder strips, which was similar in control and 
diabetics (2.08±0.34 vs 2.33±0.61 mN/mg, 2-week control vs diabetics; 1.13±0.23 vs 1.05±0.26 
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mN/mg 12-week control vs diabetics), and unaffected by removal of the urothelium (2.50±0.27 
vs 2.15±0.46 mN/mg, 2-week control vs diabetics without urothelium; 1.08±0.26 vs 1.15±0.49 
mN/mg 12-week control vs diabetics without urothelium). Isoprenaline caused relaxation of the 
KCl-pre-contracted bladder strips. Maximal relaxations to isoprenaline were similar at 2 weeks 
(-0.37±0.05 mN/mg in diabetics compared to controls -0.36±0.06mN/mg). However, when the 
urothelium was removed isoprenaline relaxations were significantly greater in strips from 2-
week diabetics compared to controls (-0.65±0.19 vs -0.29±0.07 mN/mg, P<0.05) (Fig. 5a). 
pEC50 values for isoprenaline were similar at 2 weeks (6.73±0.49 vs 5.95±0.28, diabetics vs 
controls) and removal of the urothelium did not affect these (6.73±0.49 vs 6.68±0.47, with vs 
without urothelium). Maximal responses and pEC50 values for isoprenaline were also similar in 
12-week controls and diabetics (-0.22±0.04 vs -0.16±0.01 mN/mg, pEC50 6.35±0.17 vs 
6.35±0.17). However, removal of the urothelium from bladder strips from 12-week diabetic 
animals unmasked significantly greater relaxations to isoprenaline (-0.41±0.07 mN/mg, P<0.05) 
when compared to intact 12-week diabetic strips (-0.16±0.01 mN/mg), and an increase in 
potency (6.96±0.21, P<0.05) (Fig. 5c).  
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Discussion 
The aim of the present study was specifically to investigate urothelial mediator release from 
isolated whole bladders, and the influence of the urothelium in modulating contractility of 
bladder strips from the streptozotocin-diabetic rat. The urothelium plays an important role in 
transmission of information from the bladder wall to the nervous system, and is a major source 
of non-neuronal ATP14. ATP released from urothelial cells as the bladder fills and stretches 
activates sensory nerves, via purinergic P2X3 receptors, leading to increased afferent signalling 
to the CNS, and initiating micturition and bladder emptying19. Increased urothelial ATP release 
has been associated with a number of bladder disorders, and is seen in bladder strips from 
patients with overactive bladder20 and painful bladder syndrome21, as well as in urothelial cells 
from patients with interstitial cystitis22. ATP is thought to sensitise afferent nerves and 
interstitial cells and alter bladder activity.  In the present study, ATP release into the bladder 
lumen was measured following distension with saline, to mimic bladder filling. Both low and 
high volume distensions were examined, to determine whether ATP release was altered with 
the degree of distension in diabetes.  The volume of saline infused during high volume 
distension produced an intraluminal pressure of around 25mmHg in control bladders, which is 
close to that which would normally initiate voiding23.  ATP released into the lumen following 
low volume distension was below the level of detection. However, following high volume 
distension ATP was quantifiable in all samples, suggesting that the degree of distension 
influences the amount of ATP released. The relationship between distension of the bladder and 
ATP release is not yet clear, although stretch-related ATP release has been widely reported in 
bladder strips20, 24, 25, and ATP increases in a pressure-dependent manner in the bladder in a 
number of species26-29. The degree of stretch at low volume distensions in the present study 
may not have been sufficient to activate stretch-dependent ATP release. Although in patients 
ATP release is important for sensation in the early stages of bladder filling30. An alternative 
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explanation may be that small amounts of ATP released at low volume distensions  are 
undetectable due to the activity of ecto-ATPase enzymes, which are known to be expressed 
within the urothelium31.  
 
Despite this complexity at low volume bladder distensions, ATP release following high volume 
distension was enhanced by diabetes of 2-weeks. Similarly, ATP release has been shown to be 
enhanced at 4 weeks of diabetes17. Thus, increased ATP release may be a feature of the early 
stages of diabetic bladder dysfunction. In other types of bladder dysfunction increased ATP 
release is thought to contribute to aberrant sensation and lead to altered bladder activity17, 32. In 
the present study, ATP release was not significantly greater at 12-weeks of diabetes compared 
to age-matched controls. This suggests a transition of urothelial function from a compensated 
state at 2 weeks to a decompensated state at 12 weeks, as demonstrated for a number of other 
parameters of bladder function in diabetes 6, 7, 33.  Alternatively, rather than a temporal change 
in ATP release with duration of diabetes, it may be that ATP metabolism is affected.  Whilst, 
to our knowledge there have been no reports of altered ecto-ATPase activity within the bladder 
in diabetes, activity of these enzymes is altered  in bladder tissues from patients with overactive 
bladder34. Regardless of the underlying mechanism, here we demonstrate temporal changes in 
intraluminal ATP in diabetic bladder dysfunction, which has not been reported previously.  
 
The urothelium also synthesises and releases the mediator ACh35. Whilst less well understood 
than ATP, ACh may act on the underlying cell types, playing a role in bladder sensation and 
contraction14. ACh also acts in an autocrine and paracrine manner, to stimulate release of other 
mediators including NO and ATP14, 35. In the present study ACh release was detected in 
intraluminal samples following both low and high volume distensions, although release was not 
affected by diabetes. ACh release was consistently lower following stretch to high volume 
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distension when compared to low volume distension. Non-neuronal ACh release from 
urothelial cells and human bladder strips increases with mechanical stretch35,36, and so the most 
likely explanation for these findings is that during the longer filling time associated with the 
high volume distension Ach was broken down by endogenous acetylcholinesterases, known to 
be present in the bladder mucosa37.  
 
During bladder filling the volume infused during high distension was sufficient to increase 
intraluminal pressure beyond 25mmHg in control animals, which is close to the threshold at 
which normal voiding would occur 23. However, diabetes resulted in highly compliant bladders, 
in which pressure increased very little in response to the high volume distension. This is 
consistent with previous in vivo cystometry studies, in which large increases in volume were 
needed for diabetic animals to sense a full bladder and to trigger micturition38. Other studies 
have also shown an increase in bladder weight, bladder capacity and in vivo compliance in 
diabetes12, 39. Interestingly, at 12 weeks there were also age-related changes in bladders from 
control animals, which showed similar high compliance with very little increase in pressure in 
response to the high volume distension. It is well known that bladders undergo remodelling 
with age, with a gradual loss of smooth muscle and increase in collagen, a larger filling capacity 
and functionally weaker smooth muscle and nerve-evoked contractions40.  Hence, the change 
in compliance at 12 weeks of diabetes may not reflect a diabetes-induced pathological alteration. 
 
Locally, the urothelium can influence contractility of the underlying smooth muscle41, for 
example via the release of a urothelium-derived inhibitory factor (UDIF), found in the porcine 
and human bladder42-44, but as yet unidentified. Using urothelium-intact and denuded bladder 
strips we investigated whether diabetes alters this influence of the urothelium on bladder 
contractility. Diabetes did not affect contractile responses to the muscarinic receptor agonist 
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carbachol, consistent with several previous studies45, 46, but in contrast to others showing 
depressed cholinergic contractions in 12-week diabetic bladder strips37. In addition, removal of 
the urothelium did not affect contractions in control strips. This confirms that UDIF, which 
inhibits contractile responses to carbachol in pig and human bladders42, 44, is not released from 
the rat bladder urothelium, as reported previously47.   
 
Relaxation responses of bladder strips to isoprenaline, a β-adrenoceptor agonist, were also 
unaltered by diabetes. However, removal of the urothelium unmasked greater relaxations in 
bladder strips from 2-week diabetic animals compared to denuded controls, and also enhanced 
relaxations in 12-week diabetic bladder strips relative to intact strips. These findings suggest 
that diabetes alters urothelium function in a complex manner. Both excitatory and inhibitory 
prostaglandins are released from the urothelium and are thought to influence detrusor activity48, 
and increased levels of prostaglandins are considered biomarkers for lower urinary tract 
dysfunction49.  Release of PGE2, an excitatory prostaglandin, which would oppose relaxation, 
was found to be reduced in urothelial preparations from diabetic rats16. Thus, whether our 
findings can be explained by the release of a different prostaglandin, or other excitatory 
substance, is not yet clear.  
 
Immunohistochemical studies have demonstrated reduced bladder innervation13 and decreased 
cholinergic innervation50 in diabetes.  In the present study nerve-evoked contractions of bladder 
strips were enhanced by 2 weeks of diabetes, consistent with previous functional studies12, 51. 
Interestingly, following removal of the urothelium, nerve-evoked responses of bladder strips 
from 2 weeks diabetic animals remained significantly enhanced only at lower frequencies of 
stimulation (below 5Hz). In addition, removal of the urothelium unmasked significantly greater 
contractions in 12-week diabetic strips, again at lower frequencies. Low frequency field 
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stimulation of bladder efferent nerves is thought to cause contractions mainly due to release of 
ATP, whilst cholinergic nerves are activated at higher frequencies12, 52. Whilst we did not 
investigate atropine resistance of contractions at low frequencies of stimulation, enhanced 
purinergic-mediated nerve-evoked contractions, and atropine-resistance, have been widely 
demonstrated in a number of previous studies in both diabetic rat12, 53, 54 and rabbit55 bladders, 
as well as in other types of bladder dysfunction12, 54. Munoz et al. (2013) also showed that 
changes in the non-adrenergic, non-cholinergic NANC and purinergic components of nerve-
evoked contractions is complex in diabetes, with plasticity in both NANC and P2X-mediated 
contractions, as well as muscarinic receptor-mediated alterations in NANC contractions via 
desensitisation mechanisms involving P2X2 receptors56.  The role of the urothelium in this 
complex plasticity of nerve-mediated contractions during the pathogenesis of diabetic 
dysfunction is not yet clear.  
 
In conclusion, a large percentage of patients with diabetes mellitus will develop urinary 
complications and diabetic bladder dysfunction, with a significant impact on quality of life. 
Current research is focussed on understanding the pathogenesis of diabetic bladder dysfunction. 
This study provides evidence of time-dependent functional changes within the urothelium in 
diabetes, specifically with respect to urothelial ATP release and the influence of the urothelium 
on contractility.  
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Methods 
Animal Model 
All procedures were performed in accordance with the Australian Code for the Care and Use 
of Animals for Scientific Purposes and under approval of Griffith and Bond University Animal 
Ethics Committees.  
Eight-week old male Wistar-Hannover rats were randomly allocated into four treatment groups: 
2-weeks diabetic, 2-weeks controls, 12-week diabetic, and 12-week controls.  Diabetes mellitus 
was induced via a single intraperitoneal injection of streptozotocin (65mg/kg, dissolved in 
0.01M citrate buffer, pH 4.5). Control animals were age-matched to their respective diabetic 
group. Animals were maintained under environmentally controlled conditions, with 12-hour 
light-dark cycles and free access to food and water.  
Animals were sacrificed via pentobarbital overdose (60mg/kg body weight, i.p.), 2 or 12 weeks 
following induction of diabetes.  Bladders were removed, placed into iced Krebs bicarbonate 
solution (118.4mM sodium chloride, 24.9mM sodium bicarbonate, 4.7mM potassium chloride, 
1.9mM calcium chloride, 1.15mM monopotassium phosphate and 11.7mM glucose), cleaned 
of connective tissue and whole wet bladder weight recorded. Blood was collected via cardiac 
puncture and blood glucose measured using an Accu-Check glucometer. Animals with blood 
glucose greater than 20mM were considered diabetic.  
 
Isolated Whole Bladders: Measurement of Bladder Compliance and Intraluminal Mediator 
Release 
Isolated whole bladders were cannulated with a two-way cannula via the urethra and secured 
with suture. The bladders were placed into modified tissue baths (5ml) containing gassed Krebs 
bicarbonate solution (95% O2, 5% CO2) heated to 37
oC. The cannula was connected to a syringe 
pump and a pressure transducer, connected to a PC via a 1401 interface, using “Spike 2” 
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software version 3 (Cambridge Electronic Design, Cambridge, UK), to enable recording of 
intraluminal pressure during bladder filling and emptying. Following 30 minutes of 
equilibration, bladders were filled by infusion with isotonic saline (0.9% NaCl) at a rate of 
150µl/min. Bladder distensions were performed by filling to either low volume (375µl) or high 
volume (1200µl). Following distension, the bladder was drained and intraluminal contents 
collected immediately on dry ice. These were stored at -30oC for later assay of the mediators 
ATP and ACh, as performed previously57.  Intraluminal ATP was measured using an ATP 
determination kit (Molecular Probes). This is a bioluminescence assay which determines ATP 
using luciferase and it’s substrate D-luciferin. The assay was performed according to 
manufacturer’s instructions, whereby a standard curve using known concentrations of ATP was 
constructed and used to determine ATP in the intraluminal samples. Luminescence was 
measured using a microplate reader (Modulus, Promega). ACh was measured using an Amplex 
(®) Red acetylcholine assay (Molecular Probes), performed according to manufacturer’s 
instructions. This is a fluorescence-based assay in which ACh in the samples is converted into 
choline by ACh, and the choline then oxidized by choline oxidase to betaine and hydrogen 
peroxide. Hydrogen peroxide reacts with Amplex Red reagent, in the presence of horseradish 
peroxidase, to generate the fluorescent produce resorufin. ACh in the intraluminal samples 
determined using a standard curve of known concentrations of Ach. Fluorescence was measured 
on a microplate reader (Ex. 540/Em. 590 nm). 
 
Contractility of Isolated Bladder Strips 
Whole bladders were dissected into 3-4 longitudinal strips. Half of the strips were denuded of 
the urothelium by careful dissection under a microscope. Strips were mounted in EZ-Bath tissue 
baths (GlobalTown Microtechnology, FL, USA) filled with gassed Krebs bicarbonate solution 
(370C, 95% O2/5% CO2), and allowed to equilibrate for 60 minutes under 150mN resting 
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tension, to allow examination of contractility.  Changes in isometric developed tension were 
recorded using a Power Lab data acquisition system using ‘LabChart®’ software version 7.1.1 
(AD instruments).  
Cumulative-concentration response curves to the muscarinic agonist carbachol (Sigma-Aldrich) 
were performed to observe contractile responses. Following washout and return to baseline, 
relaxation responses to cumulative concentrations of the β-adrenoceptor agonist isoprenaline 
(Sigma-Aldrich) were obtained following precontraction with KCl (40mM). In separate bladder 
strips, nerve-evoked contractions to electrical field stimulation (EFS) via platinum electrodes 
were recorded. Frequency-response curves (0.2–20 Hz) were obtained using 5s trains of pulses 
(40 V, 0.01 ms pulse width) delivered every 100 s. Tetrodotoxin (1 μM) (Sigma-Aldrich) was 
used to confirm that responses were neurogenic in nature and wet weight of bladder strips was 
recorded at the end of the experiments. 
 
Statistical Analysis  
GraphPad ‘Prism’ software (GraphPad, San Diego, CA, USA) was used to perform statistical 
analysis. For whole bladders, pressure-volume relationships were calculated, and data 
compared using unpaired two-way Student’s t-tests. Intraluminal mediator release from isolated 
whole bladder preparations was expressed as mean ± SEM of n experiments, where n was the 
number of bladders. Non-linear regression analysis of the concentration-response curves was 
used to determine the potency of the agonist (pEC50, the log of the concentration of a drug that 
produces half of the maximal response). Mean (±SEM) pEC50 values and maximum responses 
were calculated, whilst mean frequency-response curves were determined for nerve-evoked 
contractions. For contractile data n was the number of tissue strips.  Data was normalised for 
tissue weight and compared using a one-way ANOVA with Tukey’s post hoc test, or unpaired 
16 
 
 
 
two-tailed Student’s t test where appropriate, as indicated. P<0.05 was considered statistically 
significant.   
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Figure Legends 
 
Fig. 1. Bladder compliance 
Ex vivo pressure-volume relationships of isolated whole bladders from 2-week (a) (n=11) and 
12-week (b) (n=12) control and diabetic animals in response to distension, where bladders were 
filled at 150µl/min. (*P<0.05, **P<0.01, ***P<0.001 vs. respective control, Student’s t test). 
 
Fig. 2. Intraluminal ATP and ACh release from whole bladders 
Intraluminal ATP release following distension of isolated whole bladders with high volume 
(1200µl) (a) and intraluminal ACh release following distension with low (375µl) and high 
volume (b) from 2-week and 12-week control and diabetic animals (n=5-7, *P<0.05, 
***P<0.001, one-way ANOVA with Tukey). Note that ATP release was not measurable 
following distension with low volume.  
 
Fig. 3. Nerve-evoked contractions of bladder strips 
Frequency response curves of isolated bladder strips to electrical field stimulation (5s trains of 
pulses, 40 V, 0.01 ms pulse width, delivered every 100s) from 2-week (a & c) and 12-week (b 
& d) control and diabetic animals. Strips are intact (a & b) or denuded of urothelium (c & d). 
(n=6-8, *P<0.05 vs respective control, Student’s t test). 
 
Fig. 4. Contractility of bladder strips to carbachol 
Cumulative concentration-response curves showing contractions of isolated bladder strips to 
carbachol from 2-week (a) and 12-week (b) controls and diabetics. Strips are intact or denuded 
of urothelium. Data are expressed as mN/mg tissue weight (n=5-8).   
 
  
 
Fig. 5. Relaxation responses of bladder strips to isoprenaline 
Cumulative relaxation-response curves to isoprenaline in isolated bladder strips from 2-week 
denuded control and diabetic (a), 2- versus 12-week controls (b) and 12-week intact and 
denuded diabetic animals (c). Data are expressed as mN/mg tissue weight. (n=5-8, *P<0.05 
denuded diabetic vs denuded control, **P<0.001 denuded diabetic vs intact diabetic, one-way 
ANOVA with Tukey). 
 
